Background Drug-resistant tuberculosis (DR-TB) remains a major public health concern
worldwide. Bedaquiline, a novel diarylquinoline, was added to the WHO-recommended all …

Two drugs with novel mechanisms of action, the diarylquinoline bedaquiline and the
nitroimidazole delamanid—as well as pretomanid from the same class of drugs as …

Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving
treatment and there is an urgent need to scale up treatment programmes. One of the biggest …

Tuberculosis (TB) treatment is long and requires multiple drugs, likely due to various
phenotypes of TB bacilli with variable drug susceptibilities. Drugs with broad activity are …

Bedaquiline is recommended by the World Health Organization for the treatment of
multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We …

The importance of adequately managing multidrug-resistant (MDR) and extensively drug-
resistant (XDR) tuberculosis (TB) cases for TB control and elimination are underlined in the …

Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis
(MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients …

BACKGROUND: For the first time in almost 50 years, there are new drugs available for the
treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate …

ABSTRACT A population pharmacokinetic (PopPK) model of delamanid in patients with
pulmonary multidrug-resistant tuberculosis (MDR-TB) was developed using data from four …

ABSTRACT Objectives World Health Organization recommends a 7-drug 9–11-month
rifampicin-resistant tuberculosis (RR-TB) short treatment regimen (STR). To reduce the pill …